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Background. Fecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant
Clostridioides difficile infection (CDI). However, the efficacy of FMT in patients with chronic liver disease remains elusive. Aims.
We studied the effect of FMT on chronic liver disease (CLD) patients with CDI at our tertiary medical center. Methods. A
cohort of all patients who received FMT from December 2012 to May 2014 for refractory or recurrent CDI was identified.
Patients were monitored for a year after FMT. Descriptive analysis was conducted to compare the effect of FMT in patients with
and without CLD. Results. A total of 201 patients with CDI received FMT, 14 of which had a history of CLD. Nine of these
patients exhibited cirrhosis of the liver with a mean Child-Turcotte-Pugh score of 8. CDI development in these patients was
associated with recent exposure to antibiotics and was observed to be significantly different between both groups (17% of CLD
patients vs. 58% in the general cohort, p = 0:01). Four patients with CLD received >1 FMT, of which 2 did not respond to
treatment. There was no significant difference between patients with liver disease and the rest of the cohort with regard to FMT
response (12/14 (87%) vs. 164/187 (88%), p = 0:68). Conclusion. FMT is a safe and effective therapy against CDI for patients
with CLD and cirrhosis.
1. Introduction
Antibiotic resistant Clostridioides difficile infection (CDI) is a
major public health concern with a high death rate [1–3].
Fecal microbiota transplantation (FMT) dates back to 4th
century China where human fecal suspension by mouth was
used to cure food poisoning and severe diarrhea [4]. FMT
has been employed in patients with severe and recurrent
CDI who have failed multiple attempts at conventional anti-
biotic therapy. Cumulative experience from case series and
controlled trials shows that FMT is effective when used to
treat relapsing CDI [5, 6]. The high therapeutic efficacy of
FMT for recurrent CDI is an important proof of concept that
substantial modification of the gut microbiota can be an effec-
tive modality for treatment of other diseases in humans such
as primary sclerosing cholangitis, inflammatory bowel dis-
ease, and serious antibiotic-associated diarrhea [7–10].
Liver disease rates are steadily increasing over the years.
According to the World Health Organization, about 46% of
global diseases and 59% of the mortality are because of
chronic diseases and almost 35 million people in the world
die of chronic diseases [11]. Patients with cirrhosis and liver
transplant recipients are at increased risk of developing CDI
due to their frequent and prolonged hospitalizations, antibi-
otic and proton pump inhibitor use, multiple comorbidities,
and immunosuppressant therapy [12–16]. Currently, studies
on the efficacy of FMT in chronic liver disease (CLD)
patients with CDI are limited. We therefore evaluated the
clinical outcomes of FMT in patients with CLD at our ter-
tiary medical center.
Hindawi
International Journal of Hepatology
Volume 2020, Article ID 1874570, 6 pages
https://doi.org/10.1155/2020/1874570
2. Methods
2.1. Patient Selection. Patients with recurrent or refectory
CDI who received FMT from December 2012 to May 2014
were discerned and selected for analysis. The institutional
review board approved the research study. Patient confiden-
tiality was maintained prior to the analysis. Diagnosis of CLD
was conferred based on the following criteria: liver cirrhosis,
chronic hepatitis C infection, nonalcoholic steatohepatitis, or
metabolic liver disease including Wilson’s disease, alpha-1
antitrypsin deficiency, and hereditary hemochromatosis.
Furthermore, patient demographics, frequency of antibiotic
exposure, prevalence, and severity of CDI as well as comor-
bidities were incorporated during data collection. Disease
recurrence and donor history were acquired from the elec-
tronic medical record database. Patients were observed for a
year after FMT.
2.2. Patient Stratification. Diarrheal ailments are diagnosed
as CDI based on a positive stool test. In our facility, CDI is
determined by a two-step test. First, CDI is identified by
enzyme assays that detect Clostridioides difficile glutamate
dehydrogenase antigen as well as the Clostridioides difficile
toxins A and B. Thus, a positive enzyme assay for Clostri-
dioides difficile toxins A and B as well as the glutamate dehy-
drogenase antigen confers a diagnosis of CDI. Second, a
discrepancy in the immunoassay results is followed by a
polymerase chain reaction (PCR) to amplify the genes for
Clostridioides difficile toxins A and B, confirming the absence
or presence of CDI. Severe CDI was characterized as an ele-
vation in serum creatinine >1.5 times above the patient’s nor-
mal levels, white blood cell count ≥15,000 cells/μL, or serum
albumin <1.5 g/dL within 2 weeks of symptom onset [17].
CDI severity was assessed by clinical symptoms and lab-
oratory tests. Patients without laboratory results during FMT
were diagnosed with nonsevere CDI. Patients with a first epi-
sode of CDI that did not show symptomatic improvement
within 5 days were defined as primary refractory CDI. Those
with more than 1 episode of CDI in 1 year were considered to
have recurrent CDI [18].
Oral vancomycin was administered to all of our patients
before being referred for refractory or recurring CDI. Prior
antibiotic use was also included in the evaluation. FMT was
carried out through colonoscopy, nasogastric tube, or reten-
tion enema. FMT donors were primarily family members.
However, in the absence of family donors, our facility pro-
vides a cohort of FMT universal donors to patients. All of
our donors were screened for hepatitis A, B, and C; HIV
and syphilis serologies; stool for bacterial PCR; ova and par-
asites; and Clostridioides difficile toxins. All of our patients
received fresh FMT. Patients were considered responsive to
FMT therapy when the diarrhea ceased within 7 days of
treatment. Alternatively, FMT treatment was considered
unsuccessful if the diarrhea failed to resolve within 7 days
[19]. If the diarrhea recurred at a similar severity to the ini-
tial CDI, within 90 days of FMT, the disease was described as
a relapse. Furthermore, the CDI was characterized as a new
infection if the diarrhea returned 90 days after FMT treat-
ment. Diagnosis of cirrhosis was based on imaging such as
ultrasound or computed tomography of the abdomen exhi-
biting nodularity of the liver surface in association with an
etiology for liver disease and clinical characteristics of cir-
rhosis. Decompensation was characterized as the presence
of ascites, bleeding esophageal or gastric varices, or presence
of hepatic encephalopathy.
2.3. Statistical Analysis. Continuous variables were shown as
mean ± standard deviation while categorical variables were
reported in percentages. Comparison between both study
groups was conducted using two-sample t-tests for normally
distributed numeric data. For nonnormally distributed
numeric data, the Wilcoxon rank-sum tests were used. Chi-
square tests were used for nonsparse categorical data. Statis-
tical significance was denoted as p ≤ 0:05.
3. Results
Based on FMT procedure notes, 254 patients were initially
identified. Patients with incomplete medical records or
lack of follow-up were excluded leaving 201 patients who
underwent FMT, of which 14 patients had concurrent
CLD. Nine of these patients had cirrhosis with an average
Child-Turcotte-Pugh score of 8. At the time of FMT, one
subject had received a liver transplantation 5 months
earlier. Ten of the fourteen (71%) patients with liver
disease in our study were female with a mean age of 62
years. There was a significantly greater number of patients
with recent antibiotic exposure and who subsequently
developed CDI in the general cohort group [3/14 (21%)
of CLD patients vs. 109/187 (58%) in the general cohort,
p = 0:01] (Table 1). Response to FMT did not differ
between both groups based on immunosuppression, route
of FMT delivery, number of CDIs within the last 3
months, recent hospitalization, recent surgeries, or Charl-
son Comorbidity Index (Table 2). Severe CDI rates were
similar between patients with CLD and the general cohort
[5/14 (36%) vs. 45/187 (24%), p = 0:34]. Four patients with
CLD received more than 1 FMT, of which 2 patients did
not respond to treatment. Also, none of the patients with
liver cirrhosis had worsening of their Child-Turcotte-Pugh
score after FMT.
Finally, there was no significant difference between
patients with liver disease and the rest of the cohort with
regard to FMT response (12/14 (87%) vs. 164/187 (88%),
p = 0:68).
Both of the CLD patients who did not respond to FMT
had decompensated cirrhosis with a Child-Turcotte-Pugh
scores of 9 and 12, respectively.
4. Discussion
Our study clearly shows that in patients with CLD, FMT is an
effective treatment modality in treating patients with recur-
rent CDI. Despite the promise of FMT for treatment of recur-
rent CDI, current medical literature lacks robust data on the
use of FMT for recurrent CDI in patients who have concur-
rent CLD. A study done by Allegretti et al. looked at 10
patients with primary sclerosing cholangitis, who underwent
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FMT to evaluate safety, liver enzymes, and microbiome pro-
files of primary sclerosing cholangitis patients post-FMT.
The study demonstrated that FMT from a rationally selected
donor is safe, increases microbial diversity, and may improve
alkaline phosphatase among primary sclerosing cholangitis
patients [20].
One of the fears in using FMT in patients with cirrhosis is
the theoretical risk of worsening hepatic encephalopathy by
increasing patients’ fecal load. On the contrary, however,
there have been reports that FMT has been used as a treat-
ment option for hepatic encephalopathy. In a case reported
by Kao et al., 5 FMT sessions were used to treat refractory
mild hepatic encephalopathy in a patient. The theory behind
its mechanism of action is an increase in microbiota diver-
sity, specifically the beneficial taxa that are deficient in
patients with recurrent hepatic encephalopathy [21]. Also,
in a randomized clinical trial, FMT from a rationally selected
donor reduced hospitalizations, improved cognition, and
dysbiosis in cirrhotics with recurrent hepatic encephalopa-
thy. None of the patients, however, had CDI [22]. In our
cohort of patients with compensated cirrhosis, there was no
worsening of disease state including hepatic encephalopathy
after FMT.
Based on a multicenter retrospective study by Kelly et al.
of immunocompromised CDI patients who received FMT,
short-term safety data on FMT suggests that it is well toler-
ated among immunocompromised patients. Reasons for
immunosuppression varied but included patients with
inflammatory bowel disease on immunosuppressive therapy,
solid organ transplant recipients, and patients undergoing
chemotherapy. There were no infectious complications
related to FMT in these patients [23]. In our small study,
we only had 3 immunocompromised patients in the CLD
group, who tolerated FMT very well with no infectious com-
plications. Moss et al. studied long-term taxonomic and
functional divergence from donor bacterial strains following
FMT in immunocompromised patients. There were no com-
plications reported after 1 year of following these patients
[24]. In a study by Jalanka et al. on long-term safety of
FMT, patients were followed for 3.8 years after FMT. There
was no difference in the incidence of severe diseases (inflam-
matory bowel disease, cancer, autoimmune disease, allergy,
or neurological diseases) between the patient groups [25].
The theoretical possibility of transmission of unrecog-
nized infectious agents that cause illness years later, analo-
gous to prior experience with hepatitis C and human
immunodeficiency virus, has been raised. However, it would
be assumed that such agents would induce disease in donors
as well [26]. Our donors are routinely screened for a variety
of infectious pathogens including HIV and agents of viral
hepatitis. There is a recent case report of drug-resistant E. coli
transmission from the donor, when using FMT in a clinical
trial of patients with hepatic encephalopathy [27]. Therefore,
based on recent FDA guidance, we have included drug resis-
tant pathogens in our FMT donor screening. There is also
theoretical risk of transmission of obesity and metabolic syn-
drome as previous studies have shown that transplantation of
human fecal microbiota from obese subjects to rodents has
been shown to transmit an obesity phenotype [28]. Also,
FMT from lean subjects to obese subjects with metabolic syn-
drome showed an increase in insulin sensitivity [29]. Having
said that, in the study done by Jalanka et al., weight gain did
not differ between treatment groups [25]. We did not assess
for weight change in our cohort of patients post-FMT.
Table 1: Clinical characteristics of patients stratified by chronic liver disease status.
Liver disease (N = 14) No liver disease (N = 187) p value
Age 61.5 (51.0-67.0) 71.0 (54.0-82.0) 0.13
Sex
Male 4 (28.6) 72 (38.5)
0.57
Female 10 (71.4) 115 (61.5)
Immunosuppression
No 11/14 (78.6%) 160/187 (85.6%)
0.44
Yes 3/14 (21.4%) 27/187 (14.4%)
Inflammatory bowel disease
No 12/14 (85.7%) 169/187 (90.4%)
0.64
Yes 2/14 (14.3%) 18/187 (9.6%)
Recent antibiotic exposure
No 11/14 (78.6%) 78/187 (41.7%)
0.01
Yes 3/14 (21.4%) 109/187 (58.3)
Route of fecal microbiota transplantation delivery
Colonoscopy 5/14 (35.7%) 40/187 (21.4%)
0.76
Enema 2/14 (14.3%) 73/187 (39.0%)
Nasogastric tube 7/14 (50.0%) 69/187 (36.9%)
Percutaneous endoscopic gastrostomy 0/14 (0.0%) 5/187 (2.7%)
Recent hospitalization
No 9/14 (64.3%) 99/187 (52.9%) 0.58
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Our study shows that patients with CLD were less likely
to be recently exposed to antibiotics in comparison with the
general population. This could potentially mean that patients
with CLD are more immunosuppressed; hence, they are
more at risk of acquiring CDI without being exposed to anti-
microbials. Further prospective studies need to be done to
elucidate this.
Our study has several drawbacks. First, this is a retrospec-
tive study where several patients were eliminated from the
data analysis due to inadequate medical information. Second,
treatment outcomes may have been confounded by the
absence of a systematic FMT treatment regimen and through
the use of multiple diverse donors. As such, individual micro-
biomes are diverse, comprised of multiple different microbes
which are well established to vary depending on a donor’s
age. In our study, data on donor age was not available, thus
preventing us from evaluating the effect of FMT donor age
on the treatment outcome [30].
5. Conclusions
FMT is a safe and effective option with high rates of response
in patients with chronic liver disease or cirrhosis who have
CDI. This includes patients who may be organ transplant
recipients and subject to immunosuppression. Recent antibi-
otic exposure was not a prevalent determinant for CDI in
patients with liver disease. Prospective randomized con-
trolled trials should be done, studying long-term safety and
efficacy of FMT in patients with concurrent CLD and recur-
rent CDI.
Table 2: Response to FMT, stratified by liver disease status.
Liver disease (N = 12) No liver disease (N = 164) p value
Age 59.5 (47.5-73.0) 72.0 (54.0-83.0) 0.17
Sex
Male 4 (33.3) 68 (41.5)
0.76
Female 8 (66.7) 96 (58.5)
CDI severity
Severe 3 (25.0) 37 (22.6)
0.74
Nonsevere 9 (75.0) 127 (77.4)
Diabetes mellitus
No 9 (75.0) 132 (80.5)
0.71
Yes 3 (25.0) 32 (19.5)
Hypertension
No 8 (66.7) 87 (53.1)
0.55
Yes 4 (33.3) 77 (47.0)
Chronic kidney disease
No 10 (83.3) 143 (87.2)
0.66
Yes 2 (16.7) 21 (12.8)
Cancer
No 10 (83.3) 136 (82.9)
0.99
Yes 2 (16.7) 28 (17.1)
Immunosuppression
No 10 (83.3) 138 (84.2)
0.99
Yes 2 (16.7) 26 (15.9)
Recent hospitalization
No 9 (75.0) 92 (56.1)
0.24
Yes 3 (25.0) 72 (43.9)
Recent surgery
No 12 (100.0) 152 (92.7)
0.99
Yes 0 (0.0) 12 (7.3)
Route of FMT delivery
Colonoscopy 5 (41.7) 36 (22.0)
0.3
Enema 2 (16.7) 63 (38.4)
Nasogastric tube 5 (41.7) 62 (37.8)
PEG 0 (0.0) 3 (1.8)
FMT: fecal microbiota transplantation; PEG: percutaneous endoscopic gastrostomy.
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